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RESUMO 
 
O ácido araquidônico (AA) é precursor na formação dos eicosanoides, que são mediadores 
lipídicos com uma série de funções na fisiologia e patologia humana. A maioria dos 
eicosanoides atuam como mediadores pró-inflamatórios e contribuem para o 
desenvolvimento e proliferação de tumores. Nesta tese foram avaliados dois mediadores: a 
15-deoxi-Δ12,14-PGJ2 (15d- PGJ2) e os ácidos Epoxieicosatrienoicos (EETs), ambos 
apresentam uma atividade oposta a da maioria dos eicosanoides, ou seja, com uma ação 
anti-inflamatória e antitumoral. Esses dois mediadores distintos da via do AA foram utilizados 
nesta tese em dois projetos distintos. Primeiro: A 15d- PGJ2 possui uma atividade 
antiproliferativa e induziu apoptose para diversos tipos de células tumorais, entretanto, o 
efeito da15d- PGJ2 em células de cancer da tireoide ainda estava desconhecido. Neste 
sentido, foram cultivadas in vitro células tumorais da tireoide, da linhagem TPC1, e tratadas 
com diferentes concentrações de 15d- PGJ2 (0 ate 20 µM), as células tratadas demonstraram 
uma diminuição na proliferação, e aumento na apoptose, e uma diminuição na liberação e 
expressão relativa de IL-6. Estes resultados em conjunto sugerem que a 15d- PGJ2 pode ser 
utilizada como uma nova terapia para o cancer da tireoide. Segundo: Os EETs são 
metabolizados em seus diois pela epóxi hidrolase solúvel (sEH), para manter a estabilidade 
dos EETs e a sua atividade antiiflamatoria, foi utilizado um inibidor (TPPU) para sEH em um 
modelo de periodontite induzida por Aggregatibacter actinomycetemcomitans. O tratamento 
oral com TPPU, assim como o uso de animais sEH Knockout, levou a uma redução na perda 
óssea acompanhada da diminuição de moléculas osteoclastogenicas como RANK, RANKL 
e OPG, demonstrando que a inibição farmacológica da sEH pode ter um valor terapêutico 
na periodontite e doenças inflamatórias que envolvem a reabsorção óssea.  
 
Palavras chave: Prostaglandinas, epóxi hidrolase solúvel, ácidos epoxieicosatrienoicos, 
doença periodontal, câncer de tireoide.  
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ABSTRACT 
Arachidonic acid (AA) a precursor in the formation of eicosanoids which are lipid mediators 
with a number of functions in human physiology and pathology. The most of the eicosanoids 
act as proinflammatory mediators and contribute to the development and proliferation of 
tumors. In this thesis we evaluated two mediators: 15-deoxy-Δ12,14-PGJ2 (15d- PGJ2) and 
epoxieicosatrienoic acids (EETs) both act with an opposite activity of most eicosanoids,  with 
an anti-inflammatory and and anti-tumoral action these two distinct mediators  from  AA 
pathway  were used in this thesis in two different projects. First: 15d- PGJ2, was described 
that to have an antiproliferative activity and to induce apoptosis in several types of tumor cells 
however, the effect of 15d- PGJ2 in thyroid cancer cells was unknown in this sense, we tested 
in vitro cultured thyroid tumor cells, here in TPC1 cells, and treated with different 
concentrations of 15d- PGJ2 (0 to 20 uM) the treated cells showed a decrease in proliferation 
and an increase in apoptosis and a decrease in IL-6 release and relative expression. These 
key results together demonstrate that 15d- PGJ2 can be used as a new therapy for thyroid 
cancer. Second: The EETs are converted to their diols by soluble epoxy hydrolase (sEH) to 
maintain the stability of EETs and their anti-inflammatory activity, an inhibitor (TPPU) against 
was used to sEH in a periodontitis model induced with Aggregatibacter 
actinomycetemcomitans. The oral treatment in mice with TPPU and sEH Knockout animals 
showed bone loss reduction accompanied by a decrease in the osteoclastogenic molecules, 
like RANK, RANKL and OPG, demonstrating that pharmacological inhibition of sEH may have 
therapeutic value in periodontitis and inflammatory diseases that involve bone resorption. 
 
Keys words: Prostaglandin, Epoxide Hydrolase soluble, Epoxieicostrienoic acid, Periodontal 
Disease, Thyroid Cancer.  
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APRESENTAÇÃO GERAL 
A via do ácido araquidônico (AA) resulta na síntese de mediadores lipídicos 
indispensáveis na fisiologia e patologia humana. Dentre estes mediadores, chamados de 
eicosanoides, encontram-se as prostaglandinas, leucotrienos e os ácidos 
epoxieicosatrienoicos que desempenham diversas funções bioquímicas nas células, agindo 
como mensageiros de curta distância, com ação autócrina e parácrina.  
Nas últimas décadas, diversos esforços têm sido feitos para o controle e modulação da 
via do ácido araquidônico, culminando no uso terapêutico das ações dos eicosanoides com 
o intuito de prevenir ou tratar uma serie de patologias, como a hipertensão arterial, artrite 
reumatoide, carcinomas e doença periodontal. 
 A 15-deoxi-Δ12,14-prostaglandina J2 (15d-PGJ2), é um ligante do Receptor Ativado por 
Proliferadores de Peroxissoma ɣ, esta prostaglandina possui diversas ações biológicas, 
como a capacidade anti-inflamatória e antitumoral. Neste sentido o seu uso exógeno tem 
sido utilizado para modular a resposta inflamatória, e também tem demonstrado um potencial 
terapêutico para inibir o crescimento de tumores como: mama, bexiga, pulmão e próstata, 
estes efeitos foram eficientes tanto em modelos experimentais in vivo quanto in vitro, no 
entanto o seu efeito sob o câncer de tireoide ainda está desconhecido, neste sentido foi 
avaliado o efeito in vitro da 15d-PGJ2 em células da linhagem TPC1, no câncer da tireoide.  
Os ácidos epoxieicosatrienoicos (EETs), são sintetizados a partir do AA por enzimas da 
via do citrocomo P450. Os EETs possuem diversas ações biológicas como vaso dilatadores, 
anti-inflamatórios e analgésicos. No entanto os EETs são rapidamente metabolizados pela 
enzima Epoxido Hidrolase solúvel (sEH), que converte os epóxidos dos EETs para os dióis, 
os ácidos dihidroepoxidoeicostriecos (DHET). Desta forma os EETs têm uma meia vida 
curta, dificultando o seu uso farmacológico, porém, neste sentido nos últimos anos foram 
desenvolvidos inibidores para a sEH a fim de aumentar a meia vida dos EETs, desta forma 
potencializando os seus efeitos biológicos.  
xi 
 
 
   
A doença periodontal é uma doença inflamatória crônica que acomete cerca de 70% da 
população adulta. Mediadores inflamatórios gerados na doença periodontal ativam 
osteoclastos, que promovem a reabsorção óssea.  
O periodonto é constituído por ligamentos, gengiva e osso alveolar. Estas estruturas 
promovem a fixação dos dentes na boca. A doença periodontal é caracterizada pela 
destruição destas estruturas. Sendo assim a modulação da resposta inflamatória na doença 
periodontal tem sido alvo, no intuito de reduzir a perda óssea, que se não for tratada pode 
levar a perda dos dentes.  
Diante da potencial inibição da sEH, foi hipotetizado que o uso de inibidores da sEH 
para manutenção de elevados níveis de EETs, o que traria efeitos anti-inflamatórios, teria 
um efeito benéfico para evitar a perda óssea causada pela doença periodontal.
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CAPÍTULO 1.  
Fundamentação teórica  
1. Ácido Araquidônico  
  O AA é oriundo do ácido linoleico, um ácido graxo essencial. A partir da 
formação do AA, esta molécula passa a constituir os fosfolipídios, que são 
componentes da estrutura da membrana das células. Cada fosfolipídio é 
constituído de uma molécula de glicerol que interliga a um grupo fosfato e dois 
ácidos graxo. Desta forma, o AA é um dos ácidos graxos que compõem a 
membrana celular (LEHNINGER & NELSON 2006). 
 Para iniciar a síntese da cascata do AA, é necessário que este ácido graxo 
esteja livre da membrana da célula. O processo de liberação do AA depende da 
ação de enzimas que são capazes de liberar o AA da membrana para o citoplasma. 
A fosfolipase A2 (PLA2), é a principal enzima responsável pela liberação do AA da 
membrana das células. No entanto, a clivagem do AA a partir do diacilglicerol pela 
diacilglicerol lipase, é uma via alternativa relacionada com a produção de 
endocanabinóides (LEHNINGER & NELSON 2006). 
 A PLA2 é ativada pela fosforilação, que ocorre em resposta a eventos de 
transdução de sinal desencadeados por vários estímulos, como, por exemplo, a 
ação da trombina nas plaquetas, do C5a nos neutrófilos, da bradicinina nos 
fibrobrastos, reações antígeno anticorpo nos mastócitos e lesão celular em geral, 
leva a ativação da fosfolipase A2, requer uma ação catalítica dependente de 
fosforilação, liberando o AA para o citoplasma da célula. O AA livre no citoplasma 
pode ser direcionado e metabolizado por três vias diferentes, a via da 
ciclooxigenase, lipoxigenase e do Citocromo P 450 (ONI-ORISAN, et al. 2016, 
MRUWAT, et al 2015). 
1.2  Via das Ciclooxigenases  
A COX tem duas isoformas, cada uma é originada de um gene diferente. O 
gene codificador da COX1 constitutiva, é localizado no cromossomo 9 e seu 
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produto (enzima COX 1) promove a regulação de diversas funções, como a 
proteção da mucosa gastrointestinal de ulceração. O gene codificador da enzima 
COX2 induzivél, é localizado no cromossomo 1 e sua expressão é rapidamente 
aumentada em resposta a uma variedade de citocinas pró-inflamatórias e lesões 
teciduais (BACCHI, et at 2012). A enzima COX1 participa da síntese das 
prostaglandinas responsáveis pela citoproteção gastrointestinal e função 
plaquetária, enquanto a enzima COX2 induz a síntese de prostaglandinas, como 
por exemplo a prostraglandina E2, que é responsável por induzir dor e inflamação 
(KRAEMER et al 1992; SIMMONS et al 2004). As duas isoformas, tanto a da COX-
1 quanto a COX-2 ligam-se ao retículo endoplasmático promovendo uma ação de 
endoperóxido sintase, pela catalize da incorporação de duas moléculas de oxigênio 
ao araquidonato levando à uma ciclização para produzir o endoperóxido cíclico 
(PGG2). Em seguida as COXs tem uma ação de peroxidase que converte a PGG2 
em outro endoperóxido cíclico, a PGH2 (HANG et al. 2008). A PGH2 é convertida 
através de várias sintases especificas de cada célula nas principais prostaglandinas 
como:  prostaglandina sintetase converte para prostaglandina I2, (PGI2), a 
prostaglandina E2 sintetase converte para prostaglandina E2 ( PGE2), a 
tramboxano-A sintetase converte para Tramboxano A2 (TXA2) e a prostaglandina 
D2 sintetase converte para prostaglandina D2 (PGD2); (figura 1) a PGD2 sofre uma 
desidratação e espontaneamente é formada a prostaglandina J2, Em seguida esta 
molécula sofre um rearranjo intramolecular formando a Δ12-PGJ2 que perde mais 
uma molécula de água formando a 15-deoxi-Δ12,14-PGJ2  (15d-PGJ2) (SCHER, 
PILLINGER, 2004; LAMANO-CARVALHO, 2007) 
 A 15d-PGJ2 é produzida por uma variedade de células, incluindo 
macrófagos, mastócitos, células T e plaquetas (STRAUS et al, 2000). A maioria das 
prostaglandinas tem uma meia vida curta variando entre 30 segundos à 3 minutos 
(SWEETMAN, 2005). Embora pouco esteja estabelecido sobre a farmacocinética e 
estabilidade da 15d-PGJ2, acredita-se que sua meia vida seja curta devido à 
conjugação de glutationa (GSH), o que é conhecida como uma importante via 
metabólica de prostaglandinas ciclopentônicas. (ATSMON et al., 1990; STRAUS et 
al., 2000) e que podem rapidamente ser eliminadas através do metabolismo do 
pulmão, fígado, plasma e excreção renal (HAGENS et al., 2007). 
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Durante o início do processo inflamatório, no qual encontramos um aumento 
do influxo de polimorfonucleares, há um aumento da atividade da COX2 e síntese 
de PGE2, a qual possui um papel proinflamatório intenso. No entanto, 
aparentemente, a COX2 participa da resolução da fase aguda da inflamação 
alternando o padrão da síntese de prostaglandina para a família J. (SURH et at 
2011). Além da fase aguda da inflamação, a PGE2 está envolvida também na 
inflamação crônica e no desenvolvimento de tumores malignos (OBERMAJER et al 
2012).  
 
Figura 1. Síntese da 15d-PGJ2, modificado e adaptado de Surh et al. 2011. 
 
1.2.1 15-deoxi-Δ12,14-PGJ2   
Recentemente, tem sido dada grande importância no papel da 15d-PGJ2 na 
regulação do processo inflamatório e no desenvolvimento de tumores (JIANG, 
TING, SEED, 1998; RICOTE et al., 1998; CLARK et al., 2000, LIU et al 2014), 
devido à possibilidade de intervenção farmacológica ser aplicada na regulação da 
produção de citocinas e prostaglandinas. A 15d-PGJ2,  é um dos derivados do 
metabolismo da PGD2, e um ligante natural (do inglês Peroxisome proliferator-
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activated receptor gamma) PPAR-γ (FORMAN et al., 1995; RICOTE et al., 1998), 
o que sugere que esta molécula possui um importante papel na regulação da 
reposta inflamatória e no desenvolvimento de diversos carcinomas.  
 A subfamília de receptores nucleares PPAR consiste de três diferentes 
isoformas, PPAR-α, PPAR-β/δ e PPAR-γ, as quais são codificadas por diferentes 
genes além de possuírem diferentes promotores (ZHU et al., 1995). As três 
isoformas possuem padrões distintos em relação à distribuição celular e tecidual. 
O PPAR-γ foi descrito inicialmente expresso em adipócitos e hepatócitos, porém 
atualmente, sabe-se que o PPAR-γ é encontrado em macrófagos/monócitos, 
miócitos, fibroblastos e células precursoras de medula (BRAISSANT et al., 1996).  
Acredita-se que o PPAR-γ em estado inativado esteja conjugado com 
proteínas co-repressoras, localizado no citoplasma ao invés do núcleo (BISHOP-
BAILEY, HLA, 1999). A ligação do PPAR e a 15d-PGJ2, induz a dissociação do 
PPAR de seus repressores, e permite a interação com co-ativadores (por exemplo; 
receptores esteróides), o que resulta na translocação deste do citoplasma para o 
núcleo (Zhu et al., 1997). O resultado desta translocação é a ativação da expressão 
ou repressão de uma variedade de genes que estão envolvidos no processo 
inflamatório e com o desenvolvimento e progressão de tumores (NEGISHI, KATOH, 
2002, MORIAI et al 2009). 
Napimoga et al. 2008 demonstrou que a 15d-PGJ2 (ligante natural dos 
receptores PPAR-γ) inibe a migração de neutrófilos para o sítio inflamatório inibindo 
a expressão de ICAM-1 (do inglês Intercelular Adhesion Molecule 1) no endotélio 
sendo esta ação dependente da via do óxido nítrico. Por outro lado, a 15d-PGJ2 
também foi capaz de inibir a dor inflamatória devido à liberação de opióides locais.  
Devido a sua capacidade eletrofílica a 15d-PGJ2  pode se ligar a várias 
proteínas do meio extracelular como, por exemplo, na albumina que é a proteína 
encontrada em maior concentração no plasma. Experimentos in vitro demonstram 
que mais de 90% da 15d-PGJ2 é inativada no meio extracelular, sendo assim, um 
pequeno percentual da 15d-PGJ2 administrada tem uma atividade intracelular (OH 
et al. 2008). 
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A capacidade eletrofílica da 15d-PGJ2 ocorre no anel ciclopentônico, através 
da reação de Michael, que consiste na adição nucleofílica de um carbânion ou outro 
nucleófilo a um composto carbonil α,β insaturado, que prontamente reage com 
substâncias que contenham grupos nucleofílicos, como cistenil tiol de proteínas. A 
reação seletiva da adição tiol ocorre na posição endocíclica, dentro do anel 
ciclopentônico (UCHIDA, CHIBATA, 2008).  
Como citado anteriormente, devido a sua característica eletrofílica, quando 
administrada de forma exógena sua maior parte é perdida ao se ligar a proteínas 
do soro como a albumina, sendo rapidamente degradada. Alves et al 2011, na 
tentativa de modular esta característica eletrofílica da 15d-PGJ2 desenvolveu um 
novo sistema de liberação sustentada em nanopartículas poliméricas 
biodegradáveis. Neste trabalho, a 15d-PGJ2 apresentou um efeito 33 vezes mais 
potente, quando comparada a molécula livre, na diminuição da migração de 
neutrófilos e produção de citocinas próinflamatórias em um modelo de peritonite 
induzida. Ainda utilizando este modelo de liberação sustentada, Napimoga et al 
2012, demonstrou que usando baixas doses de 15d-PGJ2 hove uma inibição da 
reabsorção óssea em um modelo de periodontite induzida. Ainda envolvendo o 
metabolismo ósseo em processos patológicos, foi investigado a atividade da 
inibição da perda óssea associada com metástase de câncer de mama e a 
deficiência de estrógeno causada pelo tratamento de câncer. A 15d-PGJ2 preveniu 
a destruição trabecular do osso femoral, atuando de forma benéfica para o 
tratamento de metástases ósseas associadas com o câncer de mama (DIERS et al 
2010) 
1.2.2 15-deoxi-Δ12,14-PGJ2  e cancer  
 O câncer e a inflamação estão relacionados pela epidemiologia, 
histopatologia, perfis inflamatórios e a eficiência de drogas anti-inflamatórias. Estas 
observações proporcionaram um impulso para a investigação e hipóteses sobre os 
mecanismos e a relação entre câncer e inflamação (RAKOFF-NAHOUM 2006). 
 Em um estudo realizado com 119 pacientes, demonstrou que a PGE2  está 
aumentada e associada com a proliferação e invasão do câncer de endométrio (KE 
et al 2016)  em outro trabalho, demonstrou que,  a PGE2 está envolvida no 
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desenvolvimento e proliferação na leucemia mieloide e câncer de mama 
(OBERMAYER et al 2012, BISHOP-BAILEY et al 2002), de outro modo a 15d-PGJ2 
uma prostaglandina com efeitos anti-inflamatórios, foi demonstrado que células do 
câncer de próstata foram tratadas com 15d-PGJ2, diminuiram a expressão e 
sinalização dos receptores de andrógenos, que são essenciais para o 
desenvolvimento e progressão no câncer de próstata (KAIKKONEN et al. 2013) 
O PPAR-γ está expresso em diversos tipos de câncer, (HERRERA et al 
2015). A 15d-PGJ2 e outros ligantes de PPAR-γ não prostanóides, como a classe 
dos glitazones, tem demonstrado em diversos experimentos in vitro e in vivo, 
elevada ativada antitumoral e antiangiogênico, inibindo consideravelmente o 
crescimento de células tumorais e induzindo apoptose em células de câncer de 
mama, cólon e pulmão (ALLRED et al. 2005; FROHLICH; WAHL, 2015; HORITA et 
al 2015).  
Foi demonstrado que enquanto a 15d-PGJ2 é capaz de inibir a atividade do 
NF-B e a produção de óxido nítrico em células de cultura de micróglia, outro 
agonista de PPAR- o troglitazone não teve nenhum efeito, indicando que a 15d-
PGJ2 pode ser mais eficaz que outros agonistas de PPAR- (PETROVA, AKAMA, 
VAN-ELDIK, 1999) e com mecanismos independentes de PPAR-; (CHAWLA et al., 
2001)  alguns destes efeitos podem ser mediados através de interações covalentes 
entre a 15d-PGJ2 e proteínas intracelulares conferindo melhores propriedades 
imunofarmacológicas se comparado aos glitazonas. Além do fator nuclear-қB (NF-
қB) e a via de sinalização ERK também sido modulada pela 15d-PGJ2 independente 
de PPAR (SCHER, PILLINGER, 2005).  
 
1.3 Via da lipoxigenase 
 Uma vez liberado, o AA pode ser metabolizado pela via da lipoxigenase que 
tem como enzima chave a 5-Lipoxigenase (FUNK, 2001; HIKIJI et al., 2008), que a 
partir do AA promove a formação do leucotrieno A4, que podem sofrer hidrolise 
enzimática e formar o leucotrieno B4 (LTB4) ou ser conjugado com glutamina dando 
origem ao leucotrieno C4 e subsequentemente ao D4 e E4 (LTC4, LTD4 e LTE4) 
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(HAEGGSTROM; WETTERHOLM, 2002). Os leucotrienos atuam como 
mediadores próinflamatórios onde o grupo LTC4, LTD4 e LTE4 são produzidos 
predominantemente por basófilos, mastócitos e eosinófilos enquanto macrófagos e 
neutrófilos geram LTB4 (FUNK; CHEN, 2000; FUNK, 2001). Inibidores da via da 
lipoxigenase tem demonstrado efeitos promissores na redução de mediadores 
proinflamatorios (WERZ; STEINHILBER, 2006).  
1.4 Via do Citocromo P450 epoxIgenase 
Os ácidos Epóxieicosatrienoicos (EETs) são produtos do metabolismo do 
ácido araquidônico, catalisados pelo citocromo P450 epoxigenase, os EETs 
possuem importantes atividades biológicas como vasodilatadores e propriedades 
anti-inflamatórias. Através da ação da enzima Epoxido Hidrolase solúvel (sEH) os 
EETs são convertidos em ácidos Dihidroxieicosatrienoicos (DHET), esta forma de 
diol, tem uma ação biológica bem reduzida, sendo assim a inibição da sEH tem sido 
proposto com uma abordagem para o tratamento da hipertensão e modulação das 
respostas inflamatórias (NORWOOD et al 2010). 
A inflamação crônica é um fator importante que contribui para uma variedade 
de doenças humanas, incluindo artrite reumatoide, doença periodontal, psoríase e 
aterosclerose. Em condições fisiológicas o ácido araquidônico encontra-se 
esterificado nos fosfolipídios de membrana sendo mobilizados durante o processo 
inflamatório pela fosfolipase A2 que é ativada por estímulos químicos, mecânicos 
e produtos bacterianos, a epoxidação do ácido araquidônico por enzimas do 
citocromo P450 promovem a conversão para EETs, que tem uma variedade de 
efeitos biológicos, incluindo a modulação da inflamação (HUANG et al 2016). 
Recentemente, foi demonstrado que a administração de EETs em ratas 
ovariectomizadas, impediu a perda óssea em modelo experimental de osteoporose, 
e inibiu a osteoclastogênese tanto in vitro como in vivo. Este resultado foi possível, 
pois o EETs inibiram múltiplas vias intracelulares após a ativação do RANK 
(Receptor ativador do fator nuclear k B), incluindo MAPKs (Proteíno-quinases 
ativadas por mitógenos), NF-kB, AP-1 (Ativator protein 1), PI3K, e ROS (Espécie 
reativa de oxigênio). Além disso, os EETs diminuíram os níveis séricos da razão 
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RANKL/OPG, TNF-α e IL-1β, que podem também ter contribuído para a atenuação 
da osteoclastogênese (GUAN et al., 2015).  
 No entanto, os EETs como descrito acima, tem uma meia vida curta o que 
dificulta seu uso farmacológico, porém, existem alguns inibidores da enzima sEH a 
fim de impedir a sua metabolização em diol e que poderiam ser utilizados como 
ferramenta farmacológica. 
1.4.1 Epoxido Hidrolase solúvel (sEH)  
Os níveis de EETs são regulados pela epóxido hidrolase solúvel (sEH), a principal 
enzima responsável pela sua degradação e conversão para um estado menos 
ativo, os ácidos dihidroxieicosatrienoicos (DHETs); limitando assim muitas das 
ações biológicas dos EETs. A sEH humana é codificada pelo gene EPHX-2 
(SANDBERG; MEIJER, 1996) localizado no braço curto do cromossomo 8 (8 p-21-
p12), com um comprimento aproximado de 45 kb, composto por 19 exons 
(LARSSON et al 1995), e nos mamíferos é uma enzima composta por dois 
monômeros de 62 kDa (CRONIN et al 2003; NEWMAN et al 2003). A sEH  é 
composta por dois domínios, separados por um curto ligante, rico em prolina . O 
domínio N-terminal apresenta uma atividade de fosfatase que hidrolisa o fosfato de 
lípidos, enquanto o domínio C-terminal exibe uma atividade epóxido hidrolase que 
converte epóxidos para os seus dióis correspondentes.  A inibição farmacológica e 
molecular da sEH tem sido estudada extensivamente para benefícios sobre o 
sistema cardiovascular. Estudos mais recentes sugerem a importância de EETs 
sob a inibição da sEH na dor e inflamação (BETTAIEB et al 2015). 
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Figura 2: Metabolismo do ácido araquidônico e efeitos fisiológicos dos metabolitos do ácido 
araquidônico. COX=Ciclooxigenase, CYP2C=Citocromo P450 2C, CYP2J=Citocromo P450 2J, 
EETs=ácidos epóxi-eicosatrienóico, DHETs= dihidroxi-eicosatrienóico, sEH=epóxi hidrolase 
solúvel, LOX=Lipoxigenase. Adaptado e modificado de Nortwood et al 2010. 
 
Kundu et al 2013, investigando a importância da quimiotaxia por MCP-1, 
descobriram que inibidores da ciclooxigenase (COX) não impediram a  migração 
de monócitos tratados com MCP-1, entretanto no mesmo experimento 
curiosamente a migração de macrófagos foi diminuída ao inibirem de forma 
farmacológica o citocromo P450 e a sEH demonstrando que este efeito era dose 
dependente com uso de inibidores. Por outro lado quando foi adicionado os DHETs 
este processo de migração foi restaurado, demonstrando que os DHETs são 
importantes mediadores no processo de quimiotaxia mediado pelo MCP-1. 
Em um trabalho utilizando um modelo de pancreatite aguda, BETTAEB et al 
2015 demonstraram que os animais tratados com inibidor de sEH apresentaram 
uma redução na produção de citocinas proinflamatórias como TNF-α, IL-1β e IL-6, 
em outro trabalho foi demonstrado que animais geneticamente modificados para 
deficiência da sEH apresentaram uma redução sistêmica de citocinas como TNF-
α, IL-1β e MCP1, quando comparados com animais não deficientes para sEH. 
(VANELLA et al 2015). 
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Estes dados demonstram a importância da inibição farmacológica da sEH, 
sendo assim está enzima se configura em um importante alvo para o tratamento e 
modulação das respostas inflamatórias. 
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ABSTRACT 
The cyclopentenone prostaglandin 15-deoxy-Δ(12,14)-prostaglandin J2 (15d-PGJ2) is 
a natural ligand of peroxisome proliferator-activated receptor gamma (PPAR-γ) and 
a potential mediator of apoptosis in cancer cells. In the present study we evaluated 
the effect of 15d-PGJ2 in human thyroid papillary carcinoma cells (TPC-1) using 
different doses of 15d-PGJ2 (0.6 to 20 µM) to determine the IC50 (9.3 uM) via the 
MTT assay. The supernatant culture medium of the TPC-1 cells that was either 
treated with 15d-PGJ2 or with the vehicle (control) for 24 hours was assessed for IL-
6 secretion via CBA assay. RT-qPCR was used to evaluate mRNA expression of 
IL-6, SOCS1, SOCS3 and STAT3. TPC-1 cells treated with 15d-PGJ2 decreased 
secretion and expression of IL-6 and STAT3, while increased SOCS1 and SOCS3. 
Overall, we demonstrated that 15d-PGJ2 downregulated the IL-6 signaling pathway 
and led TCP-1 cells into apoptosis. In conclusion, 15d-PGJ2 shows the potential to 
become a new therapeutic approach for thyroid tumors.  
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1. INTRODUCTION 
Thyroid cancer combined with some of the commonest endocrine cancers make up 
the 5th commonest neoplastic disease in humans, which are increasing in incidence 
more rapidly than any other. The treatment of thyroid cancer consists mainly of 
surgical excision and ablation of the remaining tissue using radioactive iodine, which 
is only effective in non-metastatic primary tumors. Metastatic disease and 
recurrence are mostly incurable and require advanced therapeutic strategies to 
improve survival [1]. 
  The molecular pathogenesis of thyroid cancer and several signaling pathways 
involve Signal Transducers and Activators of Transcription (STATs), which are a 
family of transcription factors that regulate cell proliferation, differentiation, 
apoptosis, immune and inflammatory responses, as well as angiogenesis [2,3]. 
Cumulative evidence has established that STAT3 plays a critical role on the 
development [4] and mediation of oncogenic signaling in many different cancers [5]. 
Phosphorylation of STAT3 can be induced via stimulation of the heterodimeric 
receptor complex by the IL-6 cytokine family, including IL-6, leukemia inhibitory 
factor, ciliary neurotrophic factor, oncostatin M, IL-11 and cardiotrophin-1 [6]. 
Moreover, STAT3 phosphorylation must be precisely controlled to maintain cellular 
homeostasis during both embryonic and adult development, requiring the 
participation of several negative regulators [7]. 
These negative regulators include cytoplasmic tyrosine phosphatases, e.g., protein 
tyrosine phosphatase 1B STAT, suppressor of cytokine signaling (SOCS) proteins, 
which block the cytokine receptor [8]. Loss of SOCS is known to contribute to 
abnormal activation of STAT3 in leukemia, lymphoma, hepatocellular carcinoma 
and non-small cell carcinoma of the lung [9]. 
Cyclopentenone prostaglandin 15-deoxy-Δ (12,14) -prostaglandin J2 (15d-PGJ2), 
which is an endogenous molecule generated from the dehydration of PGD2, is a 
natural ligand of peroxisome proliferator-activated receptor gamma (PPAR-γ) and a 
potential mediator of apoptosis [10]. 15d-PGJ2 has recently been demonstrated to 
exert both anti-inflammatory and anti-neoplastic effects in different cell lines and 
mouse models [11, 12, 13, 14, 15], although such effects have been shown to be 
largely independent from PPAR-γ [10], many of which are mediated via redox-
modulating transcription factors, such as nuclear factor-kappaB (NF-kB), signal 
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transducers and activators of transcription 3 (STAT3), nuclear factor-erythroid 2p45 
(NF-E2)-related factor (Nrf2), activator protein-1 (AP-1), hypoxia inducible factor, 
p53 and peroxiredoxins [16]. The electrophilic carbonyl group present in the 15d-
PGJ2 cyclopentenone ring has been suggested as the main culprit for most such 
non-prostaglandin-like effects, since it promptly reacts with cysteine thiol groups of 
proteins that can be critical in the proliferative machinery of the cell [10].  
Considering the cumulative evidence pointing towards a potent anti-neoplastic 
effect of 15d-PGJ2 as well as the scarcity of studies investigating its effects on 
thyroid malignancies [17], the aim of this study was to evaluate the 
chemotherapeutic effect of 15d-PGJ2 in thyroid cancer cells in vitro. 
 
2. MATERIALS AND METHODS.  
2.1 Cell line.  
A papillary thyroid cancer (TPC-1) cell line was selected and cultured in Dulbecco 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
in humidified 5% CO2 atmosphere at 37ºC. A normal fibroblast cell line (FG11) was 
cultured under the same conditions and used as control for cytotoxicity. 
2.2 Analysis of cell viability 
The effect of 15d-PGJ2 on TCP-1 viability was evaluated using the MTT assay. 
Briefly, thyroid cancer cells were seeded in triplicates in 96-well plates containing 
200 μL of DMEM + 10% FBS (1x104 cells per well) and incubated with 15d-PGJ2 at 
concentrations ranging from 0.6 to 20 µM for 72 hours. Cells from each well were 
treated with 10 μL solution 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma-Aldrich) and plates were incubated for additional 4 h at 37°C. 
Sulfuric acid at 2N (200 μL/well) was added and mixed thoroughly to dissolve the 
dark-blue crystals. Absorbance of the converted dye was measured by 
spectrophotometry using a microplate reader at 570 nm (test) and 650 nm 
(reference). Cell survival was calculated as percentage of MTT inhibition as follows: 
% survival = (mean experimental absorbance/ mean control absorbance) × 100. 
FG11 cells were also seeded as described above for TCP-1 cells. They were then 
incubated with 15d-PGJ2 at concentrations ranging from 5 to 15 µM for 24, 48 and 
72 hours. Cell count and viability were assessed on a Vi-Cell XR equipment 
(Beckman Coulter, USA). 
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2.3 Evaluation of apoptosis via annexin V staining 
Drug-induced apoptosis was measured using annexin V-fluorescein isothiocyanate 
(Annexin V-FITC) and PI co-staining using an Annexin V-FITC apoptosis detection 
kit (Sigma-Aldrich). After 24 hours of treatment with 15d-PGJ2, cells were rinsed and 
resuspended in 100 μL of staining solution (Annexin V-FITC and PI in HEPES 
buffer). Cells were then incubated at room temperature in the dark for 15 min, 
followed by the addition of 400 μL of binding buffer. The percentage of apoptotic 
cells was established by flow cytometry using a FACS Accuri C6 Flow (BD 
eBiosciences). 
2.4 Cytokine Analysis  
The effect of 15d-PGJ2 on cytokines production by TPC-1 cells was evaluated 
in IMDM medium from 0 to 24 hours at 37ºC and 5% CO2. This experiment was 
performed in triplicate using 24-well plates (1×104 cells/well). Cells suspensions 
were supplemented with 15d-PGJ2 at 9.3 µM per well. Cytokines present in the 
culture supernatants were analyzed by BD Cytometric Bead Array (CBA) for Human 
Th1/Th2/Th17. This method uses beads with different fluorescence intensities in 
conjunction with a cytokine-specific capture antibody. Measurements were 
performed using the FL2 and FL3 channels of the Flow Cytometer Accuri C6 Flow 
(BD eBiosciences). A specific detection kit for IL-6 was used according to the 
manufacturer’s protocols (BD eBioscience). Analysis output was obtained in the 
form of tables and charts using the FCAP ArrayTM Version 3.0 Software (BD 
eBioscience).  
2.5 mRNA expression analyses 
Quantitative real-time PCR (RT-qPCR) assays were performed using the 
Applied Biosystems 7500 Sequence Detecting system (Applied Biosystems, 
California, USA) and SYBRPremix Ex Taq II (Takara, Shiga, Japan) under the 
following reaction conditions: 40 cycles of PCR (95°C for 15 s and 60°C for 1 min) 
after an initial denaturation (95°C for 1 min). The primers used for amplification were 
as follows: SOCS3 - Forward: TCACCGAAAACACAGGTTCCA, and Reverse: 
GAGTATGTGGCTTTCCTATGCTGG; β-actin - Forward: 
CTACAATGAGCTGCGTGTGGC, and Reverse: 
CAGGTCCAGACGCAGGATGGC. Amplification of the housekeeping gene β-actin 
was used as an internal control to normalize the SOCS3 mRNA level. The RT-qPCR 
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data were presented as cycle threshold levels and were normalized against the 
corresponding β-actin control cycle threshold values. Relative gene expression was 
calculated using the 2(−ΔΔC(T)) method, as described previously [18].  
 
2.6 Statistical Analysis 
The data were analyzed on GraphPad Prism (v.6.0c) software to compare the 
effects of different treatments. Two-way ANOVA and Bonferroni's post-hoc tests 
were used to analyze the data. 
 
 
3. RESULTS 
3.1 In vitro effect of 15d-PGJ2 on TPC-1 and FG11 cell proliferation and 
viability. 
15d-PGJ2 decreased cell proliferation (Figs. 1 A and B) and cell viability at the 
concentrations of 10 µM and 20 µM (Fig. 1 C). These finding were used to calculate 
the IC50, which was established at 9.3 µM (Fig. 1D). This concentration was then 
used for subsequent experiments. The 15d-PGJ2 did not show significant effect on 
fibroblast proliferation and viability in doses varying from 5 to 15µM (Fig. 2). 
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Figure 1. 15d-PGJ2 decreased the viability of TPC1 cells. TPC1 cells were treated with 15d-PGJ2,  
(A) represent the cell culture without treatment (B) cells treated with 10 µM of 15d-PGJ2 (C) viability 
of the TPC1 cells treated with 15d-PGJ2 in the concentrations of 0 to 20 µM  (D) IC50 from cell viability 
following treatment with 15d-PGJ2. The data are presented as means + - standard deviation of three 
replicates from at least three independent tests. An asterisk * indicates statistically significant 
difference from the control (* P> 0.01; *** p> 0.001).  
 
 
 
 
 
 
 34 
 
 
Figure 2. Fibroblast (FG11) cell proliferation under 15d-PGJ2 treatment. FG11 cells were treated 
with 5 to 15 µM of 15d-PGJ2. The data are presented as means ± standard deviation of three 
replicates from at least three independent tests. 15d-PGJ2 did not show significant difference from 
the control at the doses of 5 µM, 10µM and 15µM. 
 
 
 
3.2 Apoptotic effects of 15d-PGJ2 on thyroid cancer cells  
The annexin V apoptosis assay on TPC-1 showed that 47% of the cells treated with 
15d-PGJ2 (9.3 µM) entered apoptosis, whereas less than 5% was observed in the 
control group (Fig. 3). 
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Figure 3. 15d-PGJ2 induced apoptosis in TPC1 cells.  The Annexin-V assay revealed that 15d-
PGJ2 induced 47% apoptosis in TPC-1, compared to 5% in the control group. The data are presented 
as means + - standard deviation of three replicates from at least three independent tests. An asterisk 
* indicates statistically significant difference from the control (*** p> 0.001). 
 
 
 
3.3 Relative IL-6 mRNA expression and IL-6 release by TPC-1  
The results revealed that IL-6 was highly expressed in TPC-1 and treatment with 
15d-PGJ2 decreased the relative IL-6 mRNA expression after 4 hours (Figure 4A). 
Concurrently, IL-6 release in the cell culture medium increased at a much lower rate 
than in the control group, thus demonstrating the down-modulation effect of 15d-
PGJ2 on IL-6 secretion by TPC-1 cells so soon as two hours after treatment (Figure 
4B). 
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Figure 4: decreased relative IL-6 mRNA expression and release - TPC1 cells treated with 15d-
PGJ2.  TPC1 cells were treated with 15d-PGJ2 (9,8 uM) for 0 to 24 h (A) shows the relative IL-6 
expression (B) quantitative IL-6 released by TPC-1 cells treated with 15d-PGJ2 against the control 
group. The data are presented as means + - standard deviation of three replicates from at least three 
independent tests. An asterisk * indicates statistically significant difference from the control group (* 
P> 0.01; *** p> 0.001). 
 
 
3.4 Relative expression of SOCS3, SOCS1 and STAT3 
Upregulation of SOCS1 and SOCS3 occurred rather early in TPC-1 treated with 15d-PGJ2 
(Figure 5A and B). A significant difference between the control and the treated cells was 
observed two hours after treatment, with SOCS3 showing a four-fold increase in relative 
mRNA expression. Such an effect was not long-lasting, and 4 hours after treatment the 
expression of SOCS1 and SOCS3 was normalized. STAT3 was downregulated 4 hours 
after treatment and was maintained throughout the assay, for 24 hours (Figure 5C). 
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Figure 5: SOCS 3 and SOCS1 increased in TPC-1 cells treated with 15d-PGJ2.  TPC1 cells were 
treated with 15d-PGJ2 (9,8 uM) for 0 to 24 h (A) shows the relative expression of SOCS3 (B) SOCS 
1 (C) and STAT3 (C) in the first two hours of treatment and decreased STAT3 four hours after the 
treatment (C). The date are presented as means + - standard deviation of three replicates from at 
least three independent tests. An asterisk * indicates statistically significant difference from the 
control (* P> 0.01; *** p> 0.001). 
 
 
4. DISCUSSION 
The most important adverse aspects in the current surgical approach to treat 
papillary thyroid carcinoma is the risk of long-term recurrence and the difficulty in 
managing metastatic disease, especially in those cases initially regarded as low risk 
[19, 20] In the recent past, great efforts have been made to define new molecular 
therapies to potentiate the effectiveness of current cytostatic drugs and 15d-PGJ2 
has recently emerged as a potent antineoplastic molecule [21]. 
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Several studies have demonstrated that although 15d-PGJ2 is an endogenous 
ligand of PPAR-γ, most of its anti-neoplastic effects are PPAR-γ-independent [22, 
23]. The effects of PPAR-γ ligands may also act by independent mechanisms 
because they differ widely amongst carcinoma types, and thus must be individually 
examined. 
The present study investigated the role of exogenous 15d-PGJ2 on papillary thyroid 
carcinoma cells, the TPC-1 cell line. The drug reduced cell viability at the doses of 
10 and 20 µM (Figure 1C). Similar results have been found in cell viability in cultures 
with other cell lines of breast cancer, lung cancer, lymphoma [24, 25], colorectal [26, 
27], ovarian [22], gastric [21], pancreatic [28] and prostate cancer [29]. 
Despite the overall anti-tumoral effect of 15d-PGJ2, most studies have reported both 
dose and time-dependent responses, with lower doses often promoting opposing 
effects to the cytotoxic doses [23]. Micromolar doses of 15d-PGJ2 are required to 
induce lymphoma cell death [30, 31], whereas physiological concentrations of the 
metabolite are in the range of picomolar to nanomolar [23, 32]. It has also been 
reported that high doses of 15d-PGJ2 (≥5 μmol/L) caused cytotoxicity in cultured 
neurons, whereas low concentrations of the agonists (15d-PGJ2, ≤1 μmol/L) 
suppress rat and human neuronal apoptosis and necrosis induced by H2O2 
treatment [32].  
Production of IL-6 and signaling are prerequisites for tumor progression [33]. 
Indeed, overproduction of IL-6 is commonly encountered in a variety of cancer cells 
and elevated serum IL-6 levels correlate with poor outcome in cancer patients [34, 
35, 36]. IL-6 was shown to be an autocrine proliferation factor for tumor cell lines 
[37, 38, 39]. Additionally, STAT3 has been reported to be overexpressed in nearly 
40% of all breast carcinomas due, in part, to autocrine expression of IL-6 [40]. In 
turn, paracrine IL-6 can induce autocrine IL-6 expression in cells within the tumor 
microenvironment, thus establishing an IL-6+ niche and enhancing tumor 
progression [35]. The TPC-1 cells treated with 15d-PGJ2 in the current study have 
shown a decrease in IL-6 expression and release associated with reduced cell 
proliferation, thus corroborating the aforementioned mechanism of IL-6-linked 
neoplastic progression in thyroid cancer cells. Recent studies have corroborated the 
inhibitory effect of 15d-PGJ2 on IL-6 expression both in vitro [41] and in vivo [42]. 
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Differently from normal cells, which phosphorylate STAT under stringent control, 
STAT3 is continuously phosphorylated in several neoplastic diseases via 
overproduction of agonists, such as specific cytokines, namely IL-6, and their 
respective cytokine receptors [40]. This cycle can be further enhanced via 
antagonism of negative regulators, such as SOCS and tyrosine phosphatases [43].  
STAT3 has been reported to play an important role in maintaining cancer stem cells 
both in vitro and in vivo, implicating an integral involvement of STAT3 in tumor 
initiation, progression and maintenance [4]. In fact, this signaling route is so relevant 
in tumorigenesis that targeting STAT3 in neoplastic bone marrow disease practically 
interrupted the progression of metastasis [44, 45, 46, 47]. Cumulative evidence 
points to a clear STAT3-inhibitory effect of 15d-PGJ2 in inflammatory diseases [48, 
49, 10]. However, our findings show a small and stable decrease in the relative 
expression of STAT3 in thyroid cancer cells treated with 15d-PGJ2 (Figure 5C), 
although not significant. It is possible that STAT3 phosphorylation was prevented by 
15d-PGJ2 through upregulation of SOCS3, which results in the inhibition of STAT3 
activation, as shown elsewhere [50].  
Upregulation of both SOCS3 and SOCS1 was also followed by downregulation of 
IL-6 expression in TCP-1 cells related to exposure to 15d-PGJ2. SOCS3 is an 
inducible endogenous negative regulator of STAT3, and it is suggested as a tumor 
suppressor gene [51]. Negative modulation of SOCS1 and SOCS3 is a survival 
strategy in most cancer cells [52, 53, 54]. Conversely, overexpression of such 
cytokine inhibitors may indicate an anti-proliferative response. Indeed, our results 
have demonstrated that 15d-PGJ2 increased SOCS3 on TPC-1 cells within two 
hours of contact with the drug, thus supporting the anti-oncogenic nature of this 
gene (Figure 5B). Interestingly, cells presented diminished levels of SOCS3 and 
SOCS1 six hours post treatment, which was extended to 24 hours post treatment 
(Figure 5 A and B), probably because 15d-PGJ2 was already driving cells into 
apoptosis (Figure 3). 
Regarding the downregulation of IL-6 mediated by SOCS3 overexpression, as early 
as two hours after exposure to 15d-PGJ2, and considering the detrimental effects 
and actions of IL-6 linked with tumor growth, progression, and relapse [55, 56, 57], 
the 15d-PGJ2 is presented as a novel anti-neoplastic drug. 
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Our data demonstrated that apoptosis was detectable in nearly 50% of the TPC-1 
cells treated with 15d-PGJ2, compared to 5% in the control group. We have also 
demonstrated that SOCS3 overexpression was an early event in treated cells, while 
STAT3 remained stable over 24 hours. It is known that activation of STAT3 in 
cancers leads to gene expression promoting cell proliferation and resistance to 
apoptosis [58], but 15d-PGJ2-induced SOCS3 overexpression may have prevented 
STAT3 phosphorylation [50]. Despite the premature and short-lasting effect of 15d-
PGJ2 on SOCS3, its expressive upregulation (Figure 5A) may have been high 
enough to mediate apoptotic signaling within cells [59].  
 
 
 
5. CONCLUSION 
The present study shows important anti-proliferative and apoptotic activities in 
human thyroid cancer cells induced by 15d-PGJ2, Such events are linked with 
overexpression of SOCS3 that inhibits IL-6 signaling, a key factor in many cancers. 
This is the first report on 15d-PGJ2-induced SOCS3 expression, which evidences a 
novel therapeutic option for the treatment of thyroid cancer, and other cancers that 
are dependent on IL-6 signaling.   
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Abstract  
Epoxyeicosatrienoic acids (EETs), metabolites of arachidonic acid derived from the 
cytochrome P450 (CYP450) enzymes, are mainly metabolized by soluble epoxide 
hydrolase (sEH) to their corresponding diols. EETs but not their diols, have anti-
inflammatory properties and inhibition of sEH might provide protective effects 
against inflammatory bone loss. Thus, in the present study, we tested the selective 
sEH inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) in 
a mouse model of periodontitis induced by infection with A. actinomycetemcomitans. 
Oral treatment of wild type mice with TPPU and sEH knockout (KO) animals showed 
reduced bone loss induced by A. actinomycetemcomitans. This was associated with 
decreased expression of key osteoclastogenic molecules RANK/RANKL/OPG and 
the chemokine MCP-1 in the gingival tissue without affecting bacterial counts. In 
addition, downstream kinases p38 and JNK known to be activated in response to 
inflammatory signals were abrogated after TPPU treatment or in sEH KO mice. 
Moreover, endoplasmic reticulum stress was elevated in periodontal disease but 
was abrogated after TPPU treatment and in sEH knockout mice. Together, these 
results demonstrated that sEH pharmacological inhibition may be of therapeutic 
value in periodontitis.  
  
Key words: Periodontitis, inflammation, bone, epoxyeicosatrienoic acid, soluble 
epoxide hydrolase, TPPU.  
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Introduction   
Periodontitis is a chronic inflammatory disease of the supporting tissues of 
the teeth with progressive attachment loss and bone destruction (Flemmig, 1999).  
Dysbiosis is thought to be one of the major drivers of this condition. Imbalance in 
the periodontal microbiota, more specifically the relative abundance of individual 
species of bacteria was hypothesized to affect the host–microbe interactions, 
ultimately leading to destructive inflammation and bone loss (Hajishengallis et al., 
2012). However, more recent findings bring up the possibility that overgrowth of 
bacteria may be a resulting outcome rather than the cause of periodontitis. Thus, it 
is likely that the host response to bacteria that leads to the tissue changes noted in 
gingivitis and periodontitis is the root cause (Bartold and Van Dyke, 2013).  
In chronic osteolytic inflammatory diseases such as periodontitis, the failure 
of endogenous resolution pathways seem to lead to tissue destruction and 
conversely, augmentation of these natural defensive mechanisms can be an 
effective approach to control these diseases (Van Dyke, 2011). Resolution of 
inflammation is now widely accepted as an active process, in which endogenous 
antiinflammatory and pro-resolving mechanisms actively mediate wound healing 
and tissue regeneration as opposed to fibrosis and scarring (Levy et al., 2012; 
Ortega-Gomez et al., 2013). More recent studies provide supporting evidence for 
this concept, where endogenous control of inflammation directly improves bone 
healing and regeneration and suppresses the flow of destructive inflammatory 
infiltrate into the tissue (Hasturk et al., 2007; Napimoga et al., 2012).   
 Arachidonic acid (ARA) is an omega-6 polyunsaturated fatty acid constituting the 
phospholipid domain of most cell membranes. It is released by phospholipases such 
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as cytoplasmic PLA2 and is metabolized into eicosanoids through three main routes, 
via prostaglandin-endoperoxide synthase/cyclooxygenases (PTGS/COX), 
lipoxygenases (LOX), and via the cytochrome P450s (CYP), resulting in prostanoids 
leukotrienes and hydroxy-eicosatetraenoic acids (HETE) and epoxyeicosatrienoic 
acids (EETs). The CYP enzymes that utilize ARA as a substrate mainly produce 
EETs and the ω-hydroxyl metabolites 19- and 20-HETE.  ARA is metabolized to four 
biologically active EET regioisomers, the 5,6-EET, 8,9-EET, 11,12-EET, and 14,15- 
EET. All EETs are then further metabolized into less active dihydroxy-eicosatrienoic 
acids (DHETs) by the enzyme soluble epoxide hydrolase (sEH, EC 
3.3.2.10)(Morisseau and Hammock, 2013).  
Existing drugs target the cyclooxygenase (COX) and lipoxygenase (LOX) branches 
of the ARA cascade (Marnett, 2009; Haeggstrom et al., 2010). These branches 
largely synthesize proinflammatory mediators such as the prostanoids and 
leukotrienes. Most recently discovered branch, the cytochrome P450 branch, 
however, has not been adequately exploited as a pharmaceutical target. This 
branch produces both anti- and to lesser degree pro-inflammatory metabolites, 
including the 19- and 20- hydroxy-eicosatetraenoic acids (19- and 20-HETE) 
(Williams et al., 2010). Notably, antiinflammatory epoxy fatty acids such as EETs, 
and EDPs (EpDPEs) are produced by cytochrome P450s (Spector, 2009; Imig, 
2012). EETs seem to promote the resolution of inflammation, rather than prevent, 
in a manner similar to that exhibited by mediators in the LOX pathway (Serhan et 
al., 2011). EETs reduce inflammation, but are also analgesic, anti-fibrotic and anti-
hypertensive, acting in both paracrine and autocrine fashion (Spector, 2009; 
Bettaieb et al., 2015; Harris et al., 2015). However, the in vivo instability of EETs 
because of their rapid metabolism by sEH impeded understanding the roles of these 
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lipid mediators until the development of potent and orally available sEH 
pharmacological inhibitors became available (Chacos et al., 1983; Morisseau et al., 
1999).  
The hydrolysis of EETs to DHETs by sEH was considered as an inactivation 
process in which bioactive metabolites were degraded to inactive products 
(Schmelzer et al., 2005). However, recent findings suggest that DHETs are also 
bioactive and are pro-inflammatory (Norwood et al., 2010), as are the diols linoleate 
epoxides (Viswanathan et al., 2003). Thus, sEH inhibition might be a powerful 
approach for reducing inflammation not only by stabilizing the anti-inflammatory 
mediators, but also by reducing pro-inflammatory mediator production. Furthermore, 
sEH inhibitors act in synergy with existing anti-inflammatory drugs including COX 
and LOX inhibitors(Schmelzer et al., 2006; Liu et al., 2010), as well as anti-
inflammatory phosphodiesterase (PDE) inhibitors (Inceoglu et al., 2011).  
The current study aimed to test the potential utility of sEH pharmacological 
inhibition in periodontitis, in which we evaluated the effects of sEH inhibition and 
EETs on bone loss using a mouse model of bacterial periodontitis.  
Materials and Methods   
Aggregatibacter actinomycetemcomitans (JP2) was purchased from ATCC 
(Manassas, VA) and cultured in-house under anaerobic conditions to ensure viability 
and virulance.   
Chemicals: The sEH inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-
(trifluoromethoxy)phenyl]urea was synthesized in-house, purified and chemically 
characterized as described earlier (Rose et al., 2010). The methyl ester of 
arachidonic acid was from NuChek Prep Inc (Elysian, MN). Chromatography grade 
solvents for HPLC were obtained from Fisher Scientific (Pittsburgh, PA). Standards 
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for LCMS/MS analysis were purchased from Cayman Chemical (Ann Arbor, MI). 
The EET methyl esters were synthesized, purified and characterized in-house using 
procedures published previously (Morisseau et al., 2010). The final regioisomeric 
mixture was analyzed using LC-MS/MS to ensure purity and regioisomeric ratio 
which was 2.2:1.6:1.1: 1, for 14, 15-:11, 12-:  8, 9-:  5, 6- EpETrE, respectively).   
Bacterial viability: The potential bacteriostatic or bactericidal effects of TPPU at the 
administered dose were tested in vitro. The microbial inoculum of A. 
actinomycetemcomitans was prepared and adjusted to 5 × 106 colony forming units 
(CFU)/mL in tryptic soy broth. TPPU was then dissolved to a final concentration of 
10 μM in polyethylene glycol (PEG400; Fisher Scientific, Nidderau, Germany) and 
was added and incubated at 37°C for 24 hours anaerobically. PEG400 solution 
without the inhibitor was used as a control. Experiments were performed in 
duplicates on three different days.  
Animals and Animal Care: C57BL/6 (WT, wild type) and sEH -/- (KO, knockout) male 
mice were maintained under standard conditions, 23 ± 1˚C,  12-h light–dark cycle, 
ad libitum food and water in housing facilities at UC Davis. Animals were age-
matched and each group consisted of 8 mice, 6–7 week old and weighing 20-25 g. 
All procedures were in agreement with standards for the care of laboratory animals 
as outlined in the NIH Guide for the Care and Use of Laboratory Animals. All 
procedures were performed according to institutional guidelines for animal 
experimentation and were approved by the Animal Resource Services of the 
University of California, Davis, which is accredited by the American Association for 
the Accreditation of Laboratory Animal Care.   
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Periodontitis model and treatments: Animals orally received 1x109 CFU/ml of a 
diluted culture of freshly grown A. actinomycetemcomitans JP2, in a volume of 100 
µl PBS containing 2% carboxymethylcellulose. The solution was placed into the oral 
cavity with a micropipette, and the procedure was repeated at 48 and 96 h after the 
first inoculation. Treatment with TPPU and EETs was initiated after the third 
inoculation of bacteria. The inhibitor was dissolved in PEG400 and administered at 
1mg/kg/day by oral gavage. For the treatment with EETs, we attempted to apply 
viscous solution of mixture of EET-methyl ester regioisomers dissolved in PEG400 
to the gum tissue using a fine pipette at a dose of 1 µg/kg/day. The mice received 
the entire EET dose. This was done immediately before the oral gavage with both 
groups of mice receiving TPPU or mice receiving vehicle alone. Because EETs are 
unstable in stomach acid we assume exposure is largely topical or buccal. All 
treatments continued for 15 days. The plasma and blood concentration of TPPU 
was quantified as previously described by LC–MS analysis (Ostermann et al., 2015). 
The negative control group consisted of uninfected mice (sham-infected), the 
positive control group was infected and received the vehicle only. One day after the 
treatment period (16th day), animals were sacrificed by cardiac puncture after 
anesthesia with xylazine/ketamine. Plasma and whole blood were sampled and 
frozen until analysis.  
Quantification of alveolar bone loss: Evaluation of alveolar bone loss was performed 
as described previously (Napimoga et al., 2013). Sixteen days after the third 
inoculation, animals were sacrificed, the jaws were removed, and defleshed, then 
immersed overnight in 3% hydrogen peroxide, and stained with 1% methylene blue 
in PBS. Horizontal bone loss was assessed morphometrically by measuring the 
distance between the cement–enamel junction and the alveolar bone crest of the 
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first and second molars. Measurements at 14 buccal sites per mouse (7 sites each 
on the left and right maxillary molars) were made under a microscope, pictures were 
taken and bone measurements were analyzed using the Image J software suit. 
Random and blinded measurements were taken by the same calibrated person 
(C.A.T.d.S.). Intraexaminer reproducibility of the measurements achieved >90%.  
Western Blotting: Western blotting was performed as described earlier (Bettaieb et 
al., 2013). Briefly, tissues were lysed first and clarified by centrifugation and protein 
concentrations were determined using the bicinchoninic acid protein assay kit 
(ThermoFisher Scientific, Waltham MA). Equal amounts of protein (20 µg) from the 
gingival tissue were resolved by SDS-PAGE and transferred to PVDF membranes. 
Immunoblotting of lysates was performed with antibodies for MCP1 (Biolegend; San 
Diego, CA), pp38 (Thr180/Tyr182), p38, pJNK (Thr183/Tyr185), JNK or cCasp3 
(Cell Signaling Technology; Beverly, MA), RANK, RANKL, OPG or α-Tubulin (Santa 
Cruz Biotechnology; Santa Cruz, CA). Antibodies for sEH were generated in-house 
using recombinantly expressed mouse sEH following affinity purification. After 
incubation with the appropriate secondary antibodies, proteins were visualized using 
LuminataTM Fort Western HRP substrate (Millipore). Pixel intensities of 
immunoreactive bands were quantitated using FluorChem Q Imaging software 
(Alpha Innotech). For phosphorylated proteins data were presented as 
phosphorylation level normalized to total protein expression and for non-
phosphorylated proteins as total protein expression normalized to α-Tubulin.  
Statistical analysis: The statistical analyses were performed using Prism 5.0 or the 
SigmaPlot Software Suit. The data were first examined for normality using the 
Kolmogorov-Smirnov test, and then analyzed using one-way ANOVA. If there was 
a significant among-subjects main effect for the treatment group following one-way 
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ANOVA, or one way ANOVA on ranks, post-hoc contrasts, using the Student 
Newman Keuls multiple comparison or Tukey’s all pairwise post-hoc tests. Data are 
presented as mean ± S.E.M.  
Results  
TPPU does not affect bacterial viability  
In the present study we tested the potential effects of TPPU, a potent and 
selective pharmacological inhibitor of sEH, to inhibit bone loss caused by periodontal 
disease in mouseinduced periodontitis model. TPPU or its vehicle did not have 
bacteriostatic or bactericidal effect on the cultures used to induce the periodontal 
disease. As demonstrated in Supplemental Figure 1, no change in the growth of the 
A. actinomycetemcomitans was observed in the presence or absence of TPPU.  
Chemical inhibition of sEH reduces bone loss  
There were no A. actinomycetemcomitans in the oral cavities of mice prior to 
deliberate infection. On the other hand, persistent oral colonization by the pathogen 
was confirmed in all infected animals on the last day. Next, bone loss was quantified 
in all mice (Fig. 1A). Sham-infected animals presented the lowest distance between 
CEJ (cement-enamel junction) and ABC (alveolar bone crest) during the 
experimental period (Figure 1B). On the other hand, animals orally infected with A. 
actinomycetemcomitans, but received no treatment, showed significantly greater 
bone loss when compared to the uninfected animals (Figure 1C). Animals infected 
and orally treated with  
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Figure 1: Inhibition of sEH with a potent and orally available small molecule TPPU decreases 
bone loss. Mice were inoculated with freshly grown cultures of A. actinomycetemcomitans on three 
consecutive days as described in the methods. The vehicle PEG400, TPPU (1mg/kg) and EETmethyl 
esters (1 µg/kg diluted in PEG400) were orally administered daily by gavage. Treatments continued 
until 15th day post infection and samples were obtained on the 16th day. Distance (µm) between the 
cement-enamel junction and the alveolar bone crest for all experimental groups were quantified. (A) 
The group vehicle alone developed significant bone loss, whereas groups treated with  TPPU and 
TPPU+EET-methyl esters displayed a marked reduction in bone loss. Mice receiving EET-methyl 
esters were not different than vehicle treated infected mice, suggesting the necessity of inhibiting 
sEH for EETs to display activity. (B-F) Panels display deboned and methylene blue stained teeth 
from sham (B, n=8), mice infected with A. actinomycetemcomitans (C, n=14), EETmethyl ester (1 
µg/kg/daily) treated (D, n=12), TPPU,1 mg/kg treated (E, n=13), and EET-methyl ester +TPPU 
treated groups (F, n=13). The dark stained areas indicate sites of bone loss. The results are 
expressed as mean ± SEM (*p < 0.001, One-Way ANOVA followed by Student Newman Keuls post-
hoc all pairwise comparison).  
 
EET-methyl esters at a dose of 1 µg/kg/day did not display a significant reduction in 
bone loss (Figure 1D). In contrast, mice treated with TPPU had significantly lower 
bone loss than the untreated infected animals and was comparable to the levels of 
uninfected animals (Figure 1E). Moreover, consistent with this observation the mice 
that received combination of TPPU and EET-methyl esters had significantly lower 
bone loss compared to untreated infected animals (Figure 1F). However, this 
decrease was not significantly more than the TPPU group (p=0.53). Using this 
dosing scheme, one would expect a near complete and sustained inhibition of sEH 
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activity. Blood concentration of TPPU at the end of the experiment also supports the 
argument that the target enzyme is significantly inhibited. Groups of mice that 
received TPPU and TPPU+EET-methyl esters had more than 8 µg/mL of TPPU 
detected in the blood, even after 24 h of the last oral administration (Supplemental 
Figure 2). There were no differences regarding the blood TPPU concentration in the 
group that received TPPU+EET-methyl esters. These levels reiterate the argument 
that the target enzyme is significantly inhibited (Liu et al., 2009; Liu et al., 2010; 
Rose et al., 2010). Thus, in these studies TPPU was sufficiently stable in vivo to 
provide effective concentrations throughout the course of the experiment.    
Genetic ablation of sEH recapitulates the effects of sEH inhibitor on bone loss  
 
To support the results of sEH pharmacological inhibition, we performed 
similar experiment using sEH global knockout mice. Consistent with the results 
obtained earlier, wild type mice infected with A. actinomycetemcomitans, showed 
significantly greater bone loss when compared to the uninfected animals (Figure 2). 
Remarkably, infected sEH knockout mice displayed highly significant reduction in 
bone loss, similar to the levels of uninfected group (Figure 2D and 2E). Findings 
using sEH knockout mice recapitulate observations from sEH pharmacological 
inhibition using TPPU.   
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Figure 2: Genetic inhibition of sEH by gene knockout decreases bone loss similar to chemical 
inhibitor. sEH-/- and wild type C57/B6 mice were from a UC Davis maintained colony. Mice at age 6 
weeks were infected with A. actinomycetemcomitans three consecutive times as described for Figure 
1 and at the end of the treatment period  distance (µm) between the cement-enamel junction and the 
alveolar bone crest for all experimental groups were quantified. In parallel to the results with the sEH 
inhibitor TPPU the genetic knockout of sEH resulted in significantly reduced bone loss. Panels 
display wild type sham infected (B, n=8)), sEH-/- sham infected (C, n=15), wild type mice orally 
infected with A. actinomycetemcomitans (D, n=14), and sEH-/- mice, orally infected with A. 
actinomycetemcomitans (E, n=14). The dark stained areas indicate sites of bone loss. The results 
are expressed as mean ± SEM (*p < 0.001, One-Way ANOVA followed by Student Newman Keuls 
post-hoc all pairwise comparison).  
Inhibition of sEH alters key regulators of bone remodeling  
 
To understand the basis of these effects we determined the levels of key 
regulators of bone remodeling, a highly dynamic process. The RANK/RANKL/OPG 
system is generally accepted as a master regulator of bone loss and regeneration 
(Lacey et al., 1998). RANKL synthesized by osteoblasts, cells that synthesize new 
bone, targets RANK on the osteoclasts, cells that resorb bone.  
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This stimulates bone loss by activating osteoclasts. The third arm of the system is 
osteoblast derived OPG, which is a soluble decoy receptor for RANKL and prevents 
its binding to RANK and thereby fine tuning bone remodeling. As expected, in 
infected control mice, levels of RANK, RANKL, OPG and MCP-1 in the gum tissue 
were increased, compared to uninfected animals (Figure 3). This reiterates the 
imbalance in bone remodeling process as well as increased infiltration of cells that 
mediate inflammation, arguments supported by data presented here. In contrast, 
TPPU treatment significantly reduced the expression of these biomarkers. 
Consistent with the TPPU group, animals treated with TPPU+EET-methyl esters (1 
µg/kg) displayed a nearly identical profile in the expression of all four proteins 
quantified (Figure 3). Equally importantly, in sEH KO mice infected with A. 
actinomycetemcomitans, the effects of TPPU treatment were recapitulated. More 
specifically, in sEH KO mice levels of RANK, RANKL, and MCP-1 were similar to 
TPPU treated group, while they displayed slightly higher levels of OPG (Figure 3B-
E). However, the higher levels of OPG could be seen as an advantage since this 
would lead to less bone loss. Overall, these results underline the accelerated and 
incongruent bone remodeling in periodontal disease and that these pathological 
changes can be re-calibrated by sEH deletion or pharmacological inhibition.   
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Figure 3: The dysregulated RANK/RANKL/OPG system in periodontal disease is restored by 
chemical or genetic ablation of sEH. Protein expression levels of osteoclastogenesis-related 
factors in gingival tissues from all experimental groups were investigated by Western blotting. For 
quantification, band intensity was normalized to that of α-tubulin. Protein band intensity is 
represented as arbitrary units. Density quantification included all animals and mean± SEM of each 
group (n=6 per group) are displayed in the bar graphs. (A) Original blots displaying two randomly 
selected animals.  (B) Bar graphs of mean band intensity for, RANK (B), RANKL (C), OPG (D) and 
MCP-1(E) measured for all six mice. (*p < 0.001, ‡ p<0.03, One-Way ANOVA followed by Student 
Newman Keuls post-hoc all pairwise comparison).  
 
The significant reduction in MCP-1 expression is suggestive of a decrease in 
inflammatory cell migration and therefore inflammation. Therefore, we further 
monitored key downstream kinases known to be phosphorylated in response to 
inflammatory signals. Two stress kinases, p38 and JNK activate their respective 
signaling cascades, increase inflammation, cytokine synthesis and apoptosis.  
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Figure 4: Periodontal disease mediated phosphorylation of pro-inflammatory p38 and JNK1/2 
is reduced by chemical or genetic ablation of sEH.   Phosphorylation and activation of p38 and  
JNK1/2 were quantified from all groups by normalizing band intensity to that of α-tubulin. (A) Original 
blots displaying two randomly selected animals. (B and C)  Bar graphs of phosphorylation status of 
p38 and JNK1/2. Mean band intensity is measured for all six mice and are represented as arbitrary 
units (mean ± SEM). (*p < 0.001, ‡ p=0.01, ▼p=0.024, One-Way ANOVA followed by Student 
Newman Keuls post-hoc all pairwise comparison).  
 
In the gingival tissue of infected mice, levels of pJNK (phosphorylated JNK) and 
pp38 (phosphorylated p38) were largely increased supporting the idea that 
dysregulated host responses have a pivotal role in periodontal disease. In contrast, 
treatment with TPPU, TPPU+EET-methyl esters or in sEH KO mice infected with A. 
actinomycetemcomitans, phosphorylation of both kinases were greatly reduced 
(Figure 4). These observations are consistent with the argument that sEH inhibition 
 64 
 
dampens inflammatory response in periodontal disease. 
 
Figure 5: ER stress sensors are activated in gingival tissues of mice with periodontal disease 
and reversed by inhibition of sEH (A) Original blots displaying two randomly selected animals for 
each group. (B to E) Bar graphs of phosphorylation status of PERK, eIF2α, IRE-1α and expression 
level of sXBP-1 normalized to expression of α-tubulin. Mean band intensity is measured for all six 
mice and are represented as arbitrary units (mean ± SEM). (‡ p < 0.001, *p<0.05, Kruskal-Wallis 
One Way Analysis of Variance on Ranks followed by Tukey’s all pairwise multiple comparison post-
hoc test).  
 
The sEH is a significant regulator of endoplasmic reticulum (ER) stress 
response (Bettaieb et al., 2013; Bettaieb et al., 2015; Harris et al., 2015). Therefore, 
we evaluated whether ER stressmediated pathways are active in periodontal 
disease and if sEH deletion or pharmacological inhibition attenuate ER stress 
response. We observed the activation of the two major branches of the ER stress 
signaling cascade in the gingival tissue samples. While the levels of phosphorylated 
pPERK and pIRE1α were below the detection limit in untreated wild type and sEH 
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knockout mice, they were significantly elevated in the gum tissue of mice infected 
with A. actinomycetemcomitans  
(Figure 5). Consistent with their phosphorylation, downstream targets for each ER 
stress sensor (eIF2α and spliced XBP1) were significantly elevated in infected mice. 
Phosphorylated eIF2α and spliced X-box binding protein 1 (sXbp1), were below the 
level of detection in healthy tissues but were significantly increased in mice with 
periodontal disease. Notably, sEH knockout mice infected with A. 
actinomycetemcomitans displayed significantly lower ER stress compared to wild 
type animals infected with A. actinomycetemcomitans. However, markers of ER 
stress were higher in knockout mice compared to TPPU treated wild type animals. 
This observation suggests that chemical inhibition of sEH was more efficacious in 
attenuating ER stress. On the other hand, there was no difference between TPPU 
alone or in the presence of EET–methyl esters at the concentrations tested (p > 
0.05).   
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Figure 6: Genetic ablation or chemical inhibition of sEH reduces apoptosis in gingivial tissue 
of mice infected with A. actinomycetemcomitans. (A) Original blot displaying two randomly 
selected animals for each group. Expression level of cCaspase 3 is quantified by measuring band 
intensity for all six mice for each group and normalized to the expression level of α-tubulin. (B) Bar 
graph of mean Caspase-3 band intensity, represented as arbitrary units (mean ± SEM). (*p<0.05, 
Kruskal-Wallis One Way Analysis of Variance on Ranks followed by Tukey’s all pairwise multiple 
comparison posthoc test).  
 
A consequence of activation of ER stress sensors is a decrease in general 
protein synthesis and an increase in components that assist in overcoming stress. 
However, if these compensatory mechanisms fail to restore/maintain homeostasis 
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then the cells will engage apoptosis. To determine if periodontal disease leads to 
intense inflammatory conditions and ER stress that compel the cells to activate 
apoptotic cascades we monitored the levels of cleaved Caspase-3 (Figure 6). 
Caspase-3 is activated by upstream caspases, and is an integrator and marker of 
activation of the apoptotic signaling pathway. c-Caspase-3 expression was 
exceedingly low under normal conditions, much like the other markers used in this 
study. However, infection by A. actinomycetemcomitans significantly increased the 
levels of c-Caspase-3 in all mice, but most remarkably in the vehicle control group 
(Figure 6). This supports the hypothesis that activated ER stress in periodontal 
disease is linked to cell death. In contrast, mice treated with TPPU, TPPU+EET-
methyl esters or the sEH knockout mice displayed significantly lower levels of c-
Caspase-3. This observation suggests that inhibition of sEH was largely able to 
reduce ER stress and the ensuing apoptosis. However, given the remaining 10 fold 
increase in c-Caspase-3 in treated groups, other inflammation associated apoptotic 
signaling cascades may not have been targeted by inhibition of sEH.   
Discussion  
The pathogenesis of periodontal disease is recognized as infection-induced 
inflammatory tissue destruction. At the site of tissue destruction, cytokines, and 
inflammatory mediators are elevated. The prevalence of periodontitis in the US adult 
population is estimated at over 47%. In adults aged 65 and older, 64% had either 
moderate or severe stages of periodontal disease (Eke et al.,  
2012). This prevalence rate highlights the uniqueness of periodontal disease among 
other conditions. Therefore, efforts to understand the pathophysiology of the 
disease as well as different approaches to control it should result in tremendous 
health benefits. In the present study, we demonstrated that an inhibitor of sEH 
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largely abrogates bone loss caused by periodontal disease. This seems to be based 
on the effects of inhibition of sEH to decrease key osteoclastogenic molecules, as 
well as lowering inflammation triggered ER stress and associated apoptosis in the 
gingival tissue.  
Epoxy fatty acid generation from ARA and other unsaturated fatty acids is the 
third and latest major branch of the ARA cascade. The epoxyeicosatrienoic acids 
seem to have mostly antiinflammatory functions that are in contrast to pro-
inflammatory products of the other two branches (Capdevila et al., 1981). Multiple 
cytochrome P450s form epoxy fatty acids and ARA for example is converted into 
5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET, all of which have biological activity.  
Early evidence on the anti-inflammatory effects of 11,12-EET by preventing tumor 
necrosis factor-α (TNF-α)-induced activation of NF-κB and the subsequent increase 
in VCAM-1 (vascular cell adhesion molecule-1) expression in mice is recently 
supported by other studies(Node et al., 1999; Chiamvimonvat et al., 2007). 
However, in vivo, all EET regioisomers are degraded quickly by sEH, leading to the 
production of metabolites known as dihydroxyeicosatrienoic acids (DHETs). Thus, 
in the absence of a sEH inhibitor most of the biological effects of EETs are difficult 
to observe. The potent inhibitor of sEH TPPU stabilizes the EETs and other epoxy 
fatty acids in vivo and promotes anti-inflammatory processes. The presumed 
mechanism of the therapeutic effect seems to involve homeostatic regulation of the 
RANK, RANKL and OPG system, a master regulator of  
osteoclastogenesis. Furthermore, inhibition of sEH also decreases the chemokine 
MCP-1 as would be expected from the anti-inflammatory effects of sEH inhibition. 
Overall results are nearly identical across chemical inhibitor and global knockout 
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mice, highly supportive of the idea that inhibition of sEH rather than inhibitor 
structure specific pharmacological efficacy.  
Another line of evidence reported recently also argues for the activity of EETs 
to prevent bone loss in a different experimental paradigm (Guan et al., 2015). In an 
ovariectomy induced mouse model of bone loss, administration of EETs seem to 
prevent bone loss through a similar mechanism in which EETs normalize the plasma 
RANKL to OPG ratio, while RANK levels were not reported. Instead, authors 
demonstrate suppression of RANK by the free acid forms of EETs, in bone marrow 
mononuclear cells and the RAW264.7 cell line when induced by treating the cells 
with RANKL. In the ovariectomized mice, the prominent mechanism of bone loss 
seems to be driven by decrease in OPG. In contrast, we report the levels of RANK, 
RANKL and OPG are all increased in gingival tissue by approximately 6-fold in 
response to inflammation. These differences highlight the mechanistic distinction 
between the ovariectomy and periodontal disease induced bone loss models. 
Remarkably, in TPPU treated and sEH knockout mice in our study, RANK, RANKL 
and OPG were normalized to nearly pre-infection levels suggesting a potential 
therapeutic effect. This is of course an expected difference from the earlier study 
given that EETs have short in vivo half lives and inhibition of sEH stabilizes these 
molecules by preventing their degradation by the sEH enzymatic activity. TPPU is 
easy to administer orally or in drinking water, yields high exposure and is a potent 
inhibitor of sEH (Rose et al., 2010). It is also important to highlight that in our study, 
administration of EET-methyl esters alone topically and directly onto the periodontal 
tissue did not prevent the inflammatory periodontal bone loss. However, the EET-
methyl esters in the presence of TPPU displayed detectable changes in markers of 
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ER stress (Figure 5). Overall, the findings demonstrate that inhibition of sEH is a 
viable approach to treat complex conditions that include progressive bone  
loss.   
An active periodontal lesion is characterized by the prominent infiltration of B 
and T cells (Okada et al., 1983). Adoptive transfer of RANKL+, antigen-specific T 
cells induce bone loss in rat periodontal tissue that received local injection of the T-
cell antigen. Furthermore, T and B cells are likely the major sources of RANKL in 
the inflamed gingival tissues (Kawai et al., 2006). A benefit of inhibiting the sEH in 
this study was the sharp decrease in tissue MCP-1 (CCL-2) level. The potent 
chemoattractant MCP-1 is largely seen as the driver of monocyte infiltration into the 
gingival tissue. Thus it is plausible that administration of TPPU or in the sEH 
knockout mice lower levels of MCP-1 decreased the infiltration of inflammatory cells 
and thereby led to the downregulation of the RANK- 
RANKL-OPG axis. However, it seems more likely that EETs also had a direct effect 
on the RANKRANKL-OPG axis because while markers of ER stress were mostly 
normalized, expression of RANK, RANKL and OPG were fully restored to pre-
infection levels. This observation suggests that decreased inflammatory cell 
infiltration is a distinct effect of sEH inhibition and is an additional benefit.    
Deletion of sEH and its pharmacological inhibition lead to attenuation of the 
ER stress response in several experimental models (Bettaieb et al., 2013; Harris et 
al., 2015; Inceoglu et al., 2015). This homeostatic mechanism is involved in 
numerous pathological conditions including viral and bacterial infection and 
neurodegenerative diseases (Cao et al., 2016). The ER stress system is typically 
activated in response to stressors including excessive amounts of unfolded proteins 
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in the endoplasmic reticulum. ER stress response in periodontal disease was 
recently reported (Domon et al., 2009; Kung et al., 2015; Yamada et al., 2015). 
These authors suggested that modulation of the ER stress system could have 
therapeutic effects. Consistent with their prediction, in this study we detected the 
activation of ER stress in the gingival tissue suggesting that, at the least,  ER stress  
contributed to the development and progression of periodontal disease. The 
markers of activated ER stress were attenuated by sEH pharmacological inhibition 
and deletion. Activated ER stress signaling may lead to apoptosis when cells are 
unable to maintain homeostasis. This was reported in the gingival tissue of diabetic 
rats with periodontal disease (Kang et al., 2012). Here, we demonstrate the 
activation of apoptosis in conjunction with ER stress. However, blocking ER stress 
and inflammation with TPPU was sufficient to prevent apoptosis and this was 
consistently observed in sEH-/- mice inoculated with A. actinomycetemcomitans. 
These findings are consistent with those reported earlier for periodontal disease 
models. Specifically, in diabetic rats, A. actinomycetemcomitans induced a 
caspase3-dependent response and led to increased number of cells going through 
apoptosis in the gingival epithelial and connective tissues and increased bone loss 
(Kang et al., 2012).   
Overall, the results reiterate the importance of the RANK/RANKL/OPG 
system and its crosstalk with ER stress signaling in periodontal disease. These 
interactions ultimately give rise to increased apoptosis in the gingival tissue and 
bone loss. Given the importance and the epidemiology of gingival diseases, 
therapeutics that selectively targets the elements of the host inflammatory 
responses should prove useful to improve oral health. Our findings strongly indicate 
that inhibition of sEH is one such therapeutic approach. Nearly identical results from 
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a small molecule inhibitor of sEH and the mice with genetic knockout of sEH support 
the idea that positively altering the bioactive lipid mediators including EETs is a 
viable approach to dampen destructive inflammation, apoptosis and bone loss in 
periodontal disease.   
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SUPPLEMENTAL FIGURES: 
 
 
Supplemental Figure 1: TPPU or its vehicle does not affect bacterial viability. The 
microbial inoculum of A. actinomycetemcomitans was prepared and adjusted to 5 × 106 
colony forming units (CFU)/mL in tryptic soy broth. TPPU was then dissolved to a final 
concentration of 10 μM in 100 % polyethylene glycol (PEG400; Fisher Scientific, Nidderau, 
Germany) and was added to the soy broth. Following incubation at 37°C for 24 hours under 
anaerobic conditions, samples serially diluted and were plated on agar plates and colony 
forming units were counted the next day. PEG400 solution without the inhibitor was used 
as a control. The results are expressed as mean ± SD.    
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Supplemental Figure 2: Blood concentration of TPPU. At the end of the 15 day treatment 
period we quantified blood levels of TPPU from TPPU and   TPPU + EET-methyl ester 
treated groups. The samples were taken at 24 h after the last oral gavage treatment. In both 
treatment groups TPPU levels were well above the theoretical IC90 levels by a large margin 
suggesting strong and systemic inhibition of sEH activity. The results are expressed as 
mean ± SD from six mice per grou
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The cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J
2
(15d-PGJ
2
) is a natural ligand of peroxisome proliferator-
activated receptor gamma (PPAR-𝛾) and a potential mediator of apoptosis in cancer cells. In the present study, we evaluated the
effect of 15d-PGJ
2
in human thyroid papillary carcinoma cells (TPC-1) using different doses of 15d-PGJ
2
(0.6 to 20𝜇M) to determine
IC
50
(9.3𝜇M) via the MTT assay. The supernatant culture medium of the TPC-1 cells that was treated either with 15d-PGJ
2
or with
vehicle (control) for 24 hours was assessed for IL-6 secretion via CBA assay. RT-qPCRwas used to evaluate mRNA expression of IL-
6, SOCS1, SOCS3, and STAT3. TPC-1 cells treated with 15d-PGJ
2
decreased the secretion and expression of IL-6 and STAT3, while
it increased SOCS1 and SOCS3. Overall, we demonstrated that 15d-PGJ
2
downregulated IL-6 signaling pathway and led TPC-1 cells
into apoptosis. In conclusion, 15d-PGJ
2
shows the potential to become a new therapeutic approach for thyroid tumors.
1. Introduction
Thyroid cancer combined with some of the commonest
endocrine cancers shows as the 5th commonest neoplastic
disease in humans, which are increasing in incidence more
rapidly than any other type. The treatment of thyroid cancer
consists mainly of surgical excision and ablation of the
remaining tissue using radioactive iodine, which is only
effective in nonmetastatic primary tumors.Metastatic disease
and recurrence are mostly incurable and require advanced
therapeutic strategies to improve survival [1].
Themolecular pathogenesis of thyroid cancer and several
signaling pathways involve signal transducers and activators
of transcription (STATs), which are a family of transcription
factors that regulate cell proliferation, differentiation, apop-
tosis, immune and inflammatory responses, and angiogenesis
[2, 3]. Cumulative evidence has established that STAT3 plays
a critical role in the development [4] and mediation of
oncogenic signaling in many different cancers [5]. Phospho-
rylation of STAT3 can be induced via the stimulation of
the heterodimeric receptor complex by the IL-6 cytokine
family, including IL-6, leukemia inhibitory factor, ciliary
neurotrophic factor, oncostatin M, IL-11, and cardiotrophin-
1 [6]. Moreover, STAT3 phosphorylation must be precisely
controlled to maintain cellular homeostasis during both
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embryonic and adult development, requiring the participa-
tion of several negative regulators [7].
These negative regulators include cytoplasmic tyrosine
phosphatases, for example, protein tyrosine phosphatase 1B
STAT, suppressor of cytokine signaling (SOCS) proteins,
which block the cytokine receptor [8]. Loss of SOCS is
known to contribute to abnormal activation of STAT3 in
leukemia, lymphoma, hepatocellular carcinoma, and non-
small-cell carcinoma of the lung [9].
Cyclopentenone prostaglandin 15-deoxy-Δ12,14-pros-
taglandin J
2
(15d-PGJ
2
), which is an endogenous molecule
generated from the dehydration of PGD
2
, is a natural ligand
of peroxisome proliferator-activated receptor gamma (PPAR-
𝛾) and a potential mediator of apoptosis [10]. 15d-PGJ
2
has
recently been demonstrated to exert both anti-inflammatory
and antineoplastic effects in different cell lines and mouse
models [11–15], although such effects have been shown
to be largely independent from PPAR-𝛾 [10], many of
which are mediated via redox-modulating transcription
factors, such as nuclear factor-kappaB (NF-𝜅B), signal
transducers and activators of transcription 3 (STAT3),
nuclear factor-erythroid 2p45 (NF-E2) related factor (Nrf2),
activator protein-1 (AP-1), hypoxia inducible factor, p53,
and peroxiredoxins [16]. The electrophilic carbonyl group
present in 15d-PGJ
2
cyclopentenone ring has been suggested
as the main culprit for most such non-prostaglandin-like
effects, since it promptly reacts with cysteine thiol groups of
proteins that can be critical in the proliferative machinery of
the cell [10].
Considering the cumulative evidence pointing towards a
potent antineoplastic effect of 15d-PGJ
2
as well as the scarcity
of studies investigating its effects on thyroid malignancies
[17], the aim of this study was to evaluate the chemothera-
peutic effect of 15d-PGJ
2
in thyroid cancer cells in vitro.
2. Materials and Methods
2.1. Cell Line. Apapillary thyroid cancer (TPC-1) cell line was
selected and cultured in Dulbecco Modified Eagle Medium
(DMEM) supplementedwith 10% fetal bovine serum (FBS) in
humidified 5% CO
2
atmosphere at 37∘C. A normal fibroblast
cell line (FG11) was cultured under the same conditions and
used as control for cytotoxicity.
2.2. Analysis of Cell Viability. The effect of 15d-PGJ
2
on
TPC-1 viability was evaluated using the MTT assay. Briefly,
thyroid cancer cells were seeded in triplicate in 96-well
plates containing 200𝜇L of DMEM + 10% FBS (1 × 104 cells
per well) and incubated with 15d-PGJ
2
at concentrations
ranging from 0.6 to 20 𝜇M for 72 hours. Cells from each well
were treated with 10 𝜇L solution 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich)
and plates were incubated for additional 4 h at 37∘C. Sulfuric
acid at 2N (200𝜇L/well) was added andmixed thoroughly to
dissolve the dark-blue crystals. Absorbance of the converted
dye was measured by spectrophotometry using a microplate
reader at 570 nm (test) and 650 nm (reference). Cell survival
was calculated as the percentage ofMTT inhibition as follows:
% survival = (mean experimental absorbance/mean control
absorbance) × 100.
FG11 cells were also seeded as described above for TPC-
1 cells.They were then incubated with 15d-PGJ
2
at concentra-
tions ranging from 5 to 15 𝜇M for 24, 48, and 72 hours. Cell
count and viability were assessed on Vi-Cell XR equipment
(Beckman Coulter, USA).
2.3. Evaluation of Apoptosis via Annexin V Staining. Drug-
induced apoptosis was measured using Annexin V-fluores-
cein isothiocyanate (Annexin V-FITC) and PI costaining
using Annexin V-FITC Apoptosis Detection Kit (Sigma-
Aldrich). After 24 hours of treatment with 15d-PGJ
2
, cells
were rinsed and resuspended in 100𝜇L of staining solution
(Annexin V-FITC and PI in HEPES buffer). Cells were
then incubated at room temperature in the dark for 15min,
followed by the addition of 400 𝜇L of binding buffer.The per-
centage of apoptotic cells was established by flow cytometry
using a FACS Accuri C6 Flow (BD eBiosciences).
2.4. Cytokine Analysis. The effect of 15d-PGJ
2
on cytokines
production by TPC-1 cells was evaluated in IMDM medium
from 0 to 24 hours at 37∘C and 5% CO
2
. This experi-
ment was performed in triplicate using 24-well plates (1
× 104 cells/well). Cells suspensions were supplemented with
15d-PGJ
2
at 9.3 𝜇M per well. Cytokines present in the culture
supernatants were analyzed by BD Cytometric Bead Array
(CBA) for Human Th1/Th2/Th17. This method uses beads
with different fluorescence intensities in conjunction with a
cytokine-specific capture antibody. Measurements were per-
formed using FL2 and FL3 channels of the Flow Cytometer
Accuri C6 Flow (BD eBiosciences). A specific detection kit
for IL-6 was used according to the manufacturer’s protocols
(BD eBioscience). Analysis output was obtained in the form
of tables and charts using the FCAP Array Version 3.0
Software (BD eBioscience).
2.5. mRNA Expression Analyses. Quantitative real-time PCR
(RT-qPCR) assays were performed using the Applied Biosys-
tems 7500 Sequence Detecting system (Applied Biosystems,
California, USA) and SYBR Premix Ex Taq II (Takara, Shiga,
Japan) under the following reaction conditions: 40 cycles
of PCR (95∘C for 15 s and 60∘C for 1min) after an initial
denaturation (95∘C for 1min). The primers used for ampli-
fication were as follows: SOCS3, Forward: TCACCGAAAA-
CACAGGTTCCA and Reverse: GAGTATGTGGCTTTCC-
TATGCTGG; 𝛽-actin, Forward: CTACAATGAGCTGCGT-
GTGGC and Reverse: CAGGTCCAGACGCAGGATGGC.
Amplification of the housekeeping gene 𝛽-actin was used as
an internal control to normalize the SOCS3 mRNA level.
The RT-qPCR data were presented as cycle threshold levels
and were normalized against the corresponding 𝛽-actin
control cycle threshold values. Relative gene expression was
calculated using the 2−ΔΔCT method, as described previously
[18].
2.6. Statistical Analysis. Thedata were analyzed onGraphPad
Prism (v.6.0c) software to compare the effects of different
PPAR Research 3
(a) (b)
∗∗∗
∗
0
50
100
150
C
el
l v
ia
bi
lit
y 
(%
)
5 10 20
ANOVA
1.20.6 2.5Control
15d-PGJ2 (𝜇M)
P ≤ 0.0001
(c)
IC50 = 9.312𝜇M
0.0
0.2
0.4
0.6
0.8
1.0
1.2
TP
C-
1
(O
D
5
9
0
-O
D
6
3
0
)
5 10 15 200
15d-PGJ2 (𝜇M)
(d)
Figure 1: 15d-PGJ
2
decreased the viability of TPC-1 cells. TPC-1 cells were treated with 15d-PGJ
2
. (a) represents the cell culture without
treatment. (b) Cells treated with 10𝜇Mof 15d-PGJ
2
. (c) Viability of the TPC-1 cells treated with 15d-PGJ
2
in the concentrations of 0 to 20𝜇M.
(d) IC
50
from cell viability following treatment with 15d-PGJ
2
. The data are presented as means ± standard deviation of three replicates from
at least three independent tests. An asterisk ∗ indicates statistically significant difference from the control (∗𝑃 > 0.01; ∗∗∗𝑃 > 0.001).
treatments. Two-way ANOVA and Bonferroni’s post hoc tests
were used to analyze the data.
3. Results
3.1. In Vitro Effect of 15d-PGJ2 on TPC-1 and FG11 Cell Pro-
liferation and Viability. 15d-PGJ
2
decreased cell proliferation
(Figures 1(a) and 1(b)) and cell viability at the concentrations
of 10 𝜇Mand 20𝜇M(Figure 1(c)).These findings were used to
calculate IC50, which was established at 9.3𝜇M (Figure 1(d)).
This concentration was then used for subsequent experi-
ments. 15d-PGJ
2
did not show significant effect on fibroblast
proliferation and viability in doses varying from 5 to 15 𝜇M
(Figure 2).
3.2. Apoptotic Effects of 15d-PGJ2 onThyroidCancer Cells. The
Annexin V apoptosis assay on TPC-1 showed that 47% of
the cells treated with 15d-PGJ
2
(9.3 𝜇M) entered apoptosis,
whereas less than 5% were observed in the control group
(Figure 3).
3.3. Relative IL-6 mRNA Expression and IL-6 Release by TPC-
1. Theresults revealed that IL-6was highly expressed inTPC-
1 and treatment with 15d-PGJ
2
decreased the relative IL-6
mRNA expression after 4 hours (Figure 4(a)). Concurrently,
IL-6 release in the cell culture medium increased at a
much lower rate than in the control group, thus demon-
strating the downmodulation effect of 15d-PGJ
2
on IL-6
secretion by TPC-1 cells as soon as two hours after treatment
(Figure 4(b)).
3.4. Relative Expression of SOCS3, SOCS1, and STAT3. Upreg-
ulation of SOCS1 and SOCS3 occurred rather early in TPC-1
treated with 15d-PGJ
2
(Figures 5(a) and 5(b)). A significant
difference between the control and the treated cells was
observed two hours after treatment, with SOCS3 showing
a fourfold increase in relative mRNA expression. Such an
effect was not long-lasting, and 4 hours after treatment the
expression of SOCS1 and SOCS3 was normalized. STAT3 was
downregulated 4 hours after treatment and was maintained
throughout the assay for 24 hours (Figure 5(c)).
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Figure 2: Fibroblast (FG11) cell proliferation under 15d-PGJ
2
treatment. FG11 cells were treated with 5 to 15𝜇M of 15d-PGJ
2
.
The data are presented as means ± standard deviation of three
replications from at least three independent tests. 15d-PGJ
2
did not
show significant difference from the control at the doses of 5𝜇M,
10𝜇M, and 15𝜇M.
4. Discussion
The most important adverse aspects in the current surgical
approach to treat papillary thyroid carcinoma is the risk
of long-term recurrence and the difficulty in managing
metastatic disease, especially in those cases initially regarded
as low risk [19, 20]. In the recent past, great efforts have
been made to define new molecular therapies to potentiate
the effectiveness of current cytostatic drugs and 15d-PGJ
2
has
recently emerged as a potent antineoplastic molecule [21].
Several studies have demonstrated that although 15d-
PGJ
2
is an endogenous ligand of PPAR-𝛾, most of its antineo-
plastic effects are PPAR-𝛾-independent [22, 23]. The effects
of PPAR-𝛾 ligands may also act by independent mechanisms
because they differ widely amongst carcinoma types and thus
must be individually examined.
The present study investigated the role of exogenous 15d-
PGJ
2
on papillary thyroid carcinoma cells, the TPC-1 cell
line. The drug reduced cell viability at the doses of 10 and
20𝜇M (Figure 1(c)). Similar results have been found in cell
viability in cultures with other cell lines of breast cancer, lung
cancer, lymphoma [24, 25], and colorectal [26, 27], ovarian
[22], gastric [21], pancreatic [28], and prostate cancer [29].
Despite the overall antitumoral effect of 15d-PGJ
2
,
most studies have reported both dose and time-dependent
responses, with lower doses often promoting opposing effects
to the cytotoxic doses [23]. Micromolar doses of 15d-PGJ
2
are required to induce lymphoma cell death [30, 31], whereas
physiological concentrations of the metabolite are in the
range of picomolar to nanomolar [23, 32]. It has also been
reported that high doses of 15d-PGJ
2
(≥5 𝜇mol/L) caused
cytotoxicity in cultured neurons, whereas low concentrations
of the agonists (15d-PGJ
2
,≤1 𝜇mol/L) suppress rat and human
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Figure 3: 15d-PGJ
2
induced apoptosis in TPC-1 cells. The Annexin
V assay revealed that 15d-PGJ
2
induced 47% apoptosis in TPC-1
compared to 5% in the control group. The data are presented as
means ± standard deviation of three replicates from at least three
independent tests. ∗∗∗Statistically significant difference from the
control (P > 0.001).
neuronal apoptosis and necrosis induced by H
2
O
2
treatment
[32].
Production of IL-6 and signaling are prerequisites for
tumor progression [33]. Indeed, the overproduction of IL-
6 is commonly encountered in a variety of cancer cells and
elevated serum IL-6 levels correlate with poor outcome in
cancer patients [34–36]. IL-6 was shown to be an autocrine
proliferation factor for tumor cell lines [37–39]. Additionally,
STAT3 has been reported to be overexpressed in nearly 40%
of all breast carcinomas due, in part, to autocrine expression
of IL-6 [40]. In turn, paracrine IL-6 can induce autocrine IL-
6 expression in cells within the tumor microenvironment,
thus establishing an IL-6+ niche and enhancing tumor
progression [35]. The TPC-1 cells treated with 15d-PGJ
2
in
the current study have shown a decrease in IL-6 expression
and release associated with reduced cell proliferation, thus
corroborating the aforementionedmechanism of IL-6-linked
neoplastic progression in thyroid cancer cells. Recent studies
have corroborated the inhibitory effect of 15d-PGJ
2
on IL-6
expression both in vitro [41] and in vivo [42].
Being different from normal cells, which phosphorylate
STAT under stringent control, STAT3 is continuously phos-
phorylated in several neoplastic diseases via the overproduc-
tion of agonists, such as specific cytokines, namely, IL-6, and
their respective cytokine receptors [40]. This cycle can be
further enhanced via antagonism of negative regulators, such
as SOCS and tyrosine phosphatases [43].
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Figure 4: Decreased relative IL-6 mRNA expression and release, TPC-1 cells treated with 15d-PGJ
2
. TPC-1 cells were treated with 15d-PGJ
2
(9,8 𝜇M) for 0 to 24 h. (a) shows the relative IL-6 expression. (b) Quantitative IL-6 released by TPC-1 cells treated with 15d-PGJ
2
against the
control group. The data are presented as means ± standard deviation of three replicates from at least three independent tests. An asterisk ∗
indicates statistically significant difference from the control group (∗𝑃 > 0.01; ∗∗∗𝑃 > 0.001).
STAT3 has been reported to play an important role in
maintaining cancer stem cells both in vitro and in vivo,
implicating an integral involvement of STAT3 in tumor
initiation, progression, and maintenance [4]. In fact, this
signaling route is so relevant in tumorigenesiswhere targeting
STAT3 in neoplastic bone marrow disease practically inter-
rupted the progression of metastasis [44–47]. Cumulative
evidence points to a clear STAT3-inhibitory effect of 15d-
PGJ
2
in inflammatory diseases [10, 48, 49]. However, our
findings show a small and stable decrease in the relative
expression of STAT3 in thyroid cancer cells treated with 15d-
PGJ
2
(Figure 5(c)), although not significant. It is possible that
STAT3 phosphorylation was prevented by 15d-PGJ
2
through
the upregulation of SOCS3, which results in the inhibition of
STAT3 activation, as shown elsewhere [50].
Upregulation of both SOCS3 and SOCS1 was also fol-
lowed by the downregulation of IL-6 expression in TPC-
1 cells related to the exposure to 15d-PGJ
2
. SOCS3 is an
inducible endogenous negative regulator of STAT3, and it
is suggested as a tumor suppressor gene [51]. Negative
modulation of SOCS1 and SOCS3 is a survival strategy in
most cancer cells [52–54]. Conversely, overexpression of
such cytokine inhibitors may indicate an antiproliferative
response. Indeed, our results have demonstrated that 15d-
PGJ
2
increased SOCS3 on TPC-1 cells within two hours of
contact with the drug, thus supporting the antioncogenic
nature of this gene (Figure 5(b)). Interestingly, cells presented
diminished levels of SOCS3 and SOCS1 six hours after
treatment, which was extended to 24 hours after treatment
(Figures 5(a) and 5(b)), probably because 15d-PGJ
2
was
already driving cells into apoptosis (Figure 3).
Regarding the downregulation of IL-6 mediated by
SOCS3 overexpression, as early as two hours after exposure to
15d-PGJ
2
, and considering the detrimental effects and actions
of IL-6 linked with tumor growth, progression, and relapse
[55–57], 15d-PGJ
2
is presented as a novel antineoplastic drug.
Our data demonstrated that apoptosis was detectable
in nearly 50% of the TPC-1 cells treated with 15d-PGJ
2
,
compared to 5% in the control group. We have also demon-
strated that SOCS3 overexpression was an early event in
treated cells, while STAT3 remained stable over 24 hours. It
is known that the activation of STAT3 in cancers leads to
gene expression promoting cell proliferation and resistance to
apoptosis [58], but 15d-PGJ
2
-induced SOCS3 overexpression
may have prevented STAT3phosphorylation [50]. Despite the
premature and short-lasting effect of 15d-PGJ
2
on SOCS3,
its expressive upregulation (Figure 5(a)) may have been high
enough to mediate apoptotic signaling within cells [59].
5. Conclusion
The present study shows important antiproliferative and
apoptotic activities in human thyroid cancer cells induced
by 15d-PGJ
2
. Such events are linked with the overexpression
of SOCS3 that inhibits IL-6 signaling, a key factor in many
cancers. This is the first report on 15d-PGJ
2
-induced SOCS3
expression, which evidences a novel therapeutic option for
the treatment of thyroid cancer and other cancers that are
dependent on IL-6 signaling.
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Figure 5: SOCS3 and SOCS1 increased in TPC-1 cells treated with 15d-PGJ
2
. TPC-1 cells were treated with 15d-PGJ
2
(9,8 𝜇M) for 0 to 24 h.
(a) shows the relative expression of SOCS3 (b), SOCS1 (c), and STAT3 (c) in the first two hours of treatment and decreased STAT3 four hours
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